U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Vital Pharmaceuticals, Inc. dba VPX Sports - 04/03/2017
  1. Warning Letters

CLOSEOUT LETTER

Vital Pharmaceuticals, Inc. dba VPX Sports

Recipient:
Vital Pharmaceuticals, Inc. dba VPX Sports

United States

Issuing Office:

United States

 

  

Black HHS-Blue FDA Logo

 

 

 
5001 Campus Drive
College Park, MD 20740
 

APRIL 3, 2017

Jack Owoc
Vital Pharmaceuticals
1600 North Park Drive
Weston, FL 33326

Dear Mr. Owoc:

The Food and Drug Administration (FDA) has completed an evaluation ofyour firm's corrective actions in response to our Warning Letter 446357, issued April 24, 2015. Based on our evaluation, it appears you have addressed the violations contained in the W aming Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Latasha A. Robinson
Branch Chief
Dietary Supplement and Labeling
     Assessment Branch
Division of Enforcement
Office of Compliance
Center for Food Safety and Applied

Cc:
Marc J. Kesten
General Counsel
 

Back to Top